Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma

Munich Leukemia Laboratory (MLL), a state-of-the-art leukemia and lymphoma diagnostic and research laboratory based in Munich, has teamed up with IBM (NYSE: IBM) and Illumina, Inc. (NASDAQ: ILMN) to help build a new cognitive technology prototype that aims to help researchers improve leukemia treatment.
Source: eHealth News EU - Category: Information Technology Tags: Featured IBM Healthcare Business and Industry Source Type: news